SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.
(2020) Journal of Cystic Fibrosis — Vol. 19, n° 6, p. 872-874 (2020)
Files
SARS-CoV-2seroprevalenceinaBelgiancohortofpatientswithcysticfibrosis.pdf
Open Access - Adobe PDF
- 255.59 KB
Details
- Authors
- Abstract
- (en) BACKGROUND: In Belgium, COVID-19 epidemy began on February 4, 2020 with a peak on April 10, 2020. Patients with cystic fibrosis (CF) followed in the Cliniques universitaires Saint-Luc were rapidly isolated before the government lockdown. METHODS: After the peak of the epidemy, we measured anti-SARS-CoV-2 IgM and IgG antibodies in 149 patients and collected clinical data. RESULTS: Only 3 asymptomatic patients presented IgG against the virus. In one patient hospitalized for COVID-19 (positive molecular testing), we did not detect any anti-SARS-CoV-2 antibodies, as in thirty-five other symptomatic patients considered as possible cases. CONCLUSIONS: Even if respiratory symptoms linked to CF are frequent and compatible with COVID-19, anti-SARS-CoV-2 IgG antibodies were detected only in 3 asymptomatic patients. This reassuring study concerning the risk of COVID-19 in patients with CF illustrates the difficulty to distinguish COVID-19 symptoms from respiratory exacerbations and the need of generalized molecular testing to make a precise diagnosis.
- Affiliations
Citations
Berardis, S., Verroken, A., Vetillart, A., Struyf, C., Gilbert, M., Gruson, D., & Gohy, S. (2020). SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. Journal of Cystic Fibrosis, 19(6), 872-874. https://doi.org/10.1016/j.jcf.2020.08.005 (Original work published 2020)